YGION Biomedical receives 15 million euros
Marc Nemitz
| 21.05.2024
With 15 million euros in fresh capital, YGION Biomedical aims to redefine cancer treatment. Discover how their unique technology platform boosts the immune system
Vienna, May 21, 2024 - The Viennese biotechnology company YGION Biomedical GmbH has closed a Series A financing round of 15 million euros. The money comes from an Austrian private foundation. With this financing, YGION can further develop its YGNITE™ technology platform and the lead program YG-01 and bring them into the preclinical and clinical phase.
YGION Biomedical was founded in 2022 by biotech experts and entrepreneurs. The company focuses on the development of individualized "plug-and-play" cancer vaccines. These are based on a proprietary technology platform that identifies, produces and administers relevant neoantigen peptides in a targeted manner. This activates the patient's immune system safely and precisely.
We are on the verge of a breakthrough in individualized cancer therapy. We appreciate the confidence of our investors who are supporting us towards clinical validation of our technology.
Dr. Wolfgang Fischl, CEO of YGION
Dr. Geert Mudde, CTO of YGION, adds:"Our technology delivers simple, safe and effective cancer vaccines. The YGNITE™ platform enables us to identify and produce relevant neoantigens. In combination with our CARGONAUT™ carrier, it generates a strong and tumor-specific immune response that safely and effectively eliminates malignant cells."
YGION's lead program, YG-01, is currently in preclinical development.
About the startup
YGION Biomedical is a privately held biopharmaceutical company based in Vienna. It specializes in the development of individualized immunotherapies against cancer. YGION's YGNITE™ platform combines sequencing techniques, bioinformatics and proprietary CARGONAUT™ vaccine technology. This technology enables the production of neoepitope peptide vaccines tailored to the specific needs of each tumor and patient.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectTake care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.
Share on Linkedin Share on Facebook Share on XingFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
